Key Points
- Palvella Therapeutics COO Kathleen Goin sold 4,313 shares at an average price of $124.58, generating $537,313.54 and reducing her holdings by 66.58% to 2,165 shares. The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan.
- PVLA opened at $125.10, down 1.0%, with a market capitalization of approximately $1.80 billion. The company recently reported a quarterly loss of $1.52 per share, missing analyst expectations of a $1.17 loss.
- Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and an average price target of $209.79, although one firm maintains a sell rating. Institutional investors own about 40.11% of the company.
Palvella Therapeutics, Inc. (NASDAQ:PVLA - Get Free Report) COO Kathleen Goin sold 4,313 shares of the business's stock in a transaction on Wednesday, October 21st. The stock was sold at an average price of $124.58, for a total value of $537,313.54. Following the sale, the chief operating officer owned 2,165 shares in the company, valued at approximately $269,715.70. The trade was a 66.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Kathleen Goin also recently made the following trade(s):
- On Wednesday, September 16th, Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock. The stock was sold at an average price of $152.24, for a total transaction of $654,936.48.
- On Wednesday, August 19th, Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock. The shares were sold at an average price of $152.21, for a total transaction of $654,807.42.
Palvella Therapeutics Trading Down 1.0%
NASDAQ:PVLA opened at $125.10 on Friday. The firm has a 50-day moving average price of $142.46 and a two-hundred day moving average price of $134.48. Palvella Therapeutics, Inc. has a twelve month low of $68.96 and a twelve month high of $161.38. The company has a market capitalization of $1.80 billion, a P/E ratio of -25.90 and a beta of -0.27.
Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.35). On average, equities research analysts predict that Palvella Therapeutics, Inc. will post -6.41 earnings per share for the current year.
Analyst Upgrades and Downgrades
PVLA has been the subject of several research reports. Chardan Capital assumed coverage on Palvella Therapeutics in a research report on Monday, September 21st. They set a "buy" rating and a $240.00 price objective for the company. Raymond James Financial set a $226.00 target price on Palvella Therapeutics in a research note on Friday, October 16th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Palvella Therapeutics in a report on Friday, September 25th. HC Wainwright reissued a "buy" rating on shares of Palvella Therapeutics in a research report on Tuesday. Finally, Truist Financial set a $207.00 price target on Palvella Therapeutics in a report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Palvella Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $209.79.
View Our Latest Stock Analysis on PVLA
Institutional Investors Weigh In On Palvella Therapeutics
Hedge funds and other institutional investors have recently modified their holdings of the company. First Light Asset Management LLC raised its position in shares of Palvella Therapeutics by 38.3% in the first quarter. First Light Asset Management LLC now owns 980,758 shares of the company's stock valued at $122,251,000 after buying an additional 271,617 shares during the last quarter. BlackRock Inc. purchased a new position in shares of Palvella Therapeutics during the second quarter valued at approximately $140,343,000. Jennison Associates LLC lifted its stake in shares of Palvella Therapeutics by 65.3% during the first quarter. Jennison Associates LLC now owns 640,611 shares of the company's stock valued at $79,852,000 after buying an additional 253,128 shares during the period. Siren L.L.C. boosted its position in Palvella Therapeutics by 243.3% during the first quarter. Siren L.L.C. now owns 257,485 shares of the company's stock worth $32,096,000 after acquiring an additional 182,485 shares during the last quarter. Finally, Primecap Management Co. CA acquired a new stake in Palvella Therapeutics during the second quarter worth approximately $39,150,000. 40.11% of the stock is currently owned by hedge funds and other institutional investors.
Palvella Therapeutics Company Profile
(
Get Free Report)
Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical-stage biopharmaceutical company focused on developing treatments for patients with serious rare diseases, including conditions that may have limited or no approved therapeutic options.
The company's development programs are based on its QTORIN 3.0 technology platform, which is designed to deliver medicines locally through topical formulations. Palvella has applied the platform to investigational therapies for rare genetic skin disorders and other localized diseases, with the goal of improving treatment effectiveness while limiting systemic exposure.
Palvella is headquartered in Wayne, Pennsylvania, and conducts research and development activities aimed at serving rare-disease patients in the United States and other potential international markets.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
